ClinicalTrials.gg
Not yet recruitingNCT06337903Updated Dec 6, 2024

Self-compassion for People with Multiple Sclerosis: an Exploratory Feasibility Study

An interventional study of Self-compassion intervention (the Mindful Self-Compassion course) in Multiple Sclerosis and Self-Compassion, sponsored by Robert Simpson. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Robert Simpson · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 257 studies in Multiple Sclerosis with a site in Canada — 25 open to participants now, 43 under way, 12 of them phase 3. Multiple Sclerosis · Canada.

Planned enrollment
163rd of 215
45 · median 177
Started
2025
with 10 others
No phase
53 of 257
12 open now
Primary completion
2025-04
later than 9 of 42 live
Registered
242nd of 257
by date

Among the 257 studies in Multiple Sclerosis with a site in Canada, this one is the 163rd largest by planned enrollment of the 215 interventional ones that give a count, is one of 11 that started in 2025, is one of 53 with no phase, reaches primary completion later than 9 of the 42 other live ones, and was the 242nd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

25 of the 257 studies in Multiple Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 257 studies in Multiple Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to develop and investigate a compassion-based intervention (Mindful Self-Compassion course) in people with multiple sclerosis. The main objectives are:

  1. Explore feasibility of trial processes including recruitment, adherence, retention, and follow-up
  2. Explore experiences of people with multiple sclerosis with the Compassion-based intervention, including perceived effects, barriers and facilitators to participation, suggestions for improvement
  3. Determine potential effects on stress, anxiety, depression, emotion regulation, illness adjustment, and self-compassion.

Participants will be asked to take part in an 8-week online Mindful Self-Compassion course and report changes in levels of stress, anxiety, depression, self-compassion, adjustment, emotion, and quality of life from pre- to post-intervention and at 3-month follow-up. Additionally, participants will be asked to take part in a semi-structured interview to explore their experiences with the course, perceived effects, and suggestions for improvement.

03

Conditions studied

  • Multiple Sclerosis
  • Self-Compassion

Browse trials for

Keywords

  • Mindfulness
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older
  2. Able to understand spoken and written English
  3. Have a neurologist-confirmed diagnosis of multiple sclerosis
  4. Willing to take place in an Mindful Self Compassion course

Exclusion criteria

Exclusion Criteria:

  1. Cognitive impairment (\<26 on the )
  2. Severe active mental health impairment (psychosis, suicidality)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Self-compassion intervention

    8-week manualized online Mindful Self-Compassion course

    Behavioral: Self-compassion intervention (the Mindful Self-Compassion course)

Interventions

  • BehavioralSelf-compassion intervention (the Mindful Self-Compassion course)

    An online 8-week mindful self-compassion course with weekly sessions.

06

What researchers measure

Primary outcomes

  1. Recruitment

    The investigators will measure the number of participants eligible for and recruited to the study.

    Time frame: 4 months

  2. Retention

    The investigators will measure the percentage of participants who complete outcome data.

    Time frame: 4 months

  3. Adherence

    The investigators will measure the number of participants who completed the mindful self-compassion course.

    Time frame: 4 months

  4. Follow-up rates

    The investigators will measure the percentage of participants who complete outcome measures pre-intervention, post-intervention, and at 3 months post-intervention.

    Time frame: 4 months

Secondary outcomes

  1. Stress

    Measured using the Perceived Stress Scale-10. The total score can range from 0-40, with higher scores indicating higher perceived stress.

    Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.

  2. Anxiety

    Measured using the Hospital Anxiety and Depression Scale. The total score ranges from 0-21, with higher values representing increased anxiety symptoms.

    Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.

  3. Depression

    Measured using the Hospital Anxiety and Depression Scale. The total score ranges from 0-21, with higher values representing increased depressive symptoms.

    Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.

  4. Self-compassion

    Measured using the Self-Compassion Scale - Short Form. The total score ranges from a 1-5 Likert scale, with higher scores representing high self-compassion.

    Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.

  5. Emotion Regulation

    Measured using the Difficulties in Emotion Regulation Scale - Short Form. Answers are assessed using a 5-point Likert scale. Higher values indicate greater difficulties in emotion regulation.

    Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.

  6. Quality of Life using the Multiple Sclerosis Impact Scale (MSIS-29)

    Measured using the Multiple Sclerosis Impact Scale. Items on the scale have a Likert scale from 1-5, with a range of 0-100 total and higher scores indicating greater disability.

    Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.

  7. Participant Experiences and Perspectives

    Semi-structured interviews will aim to capture participants' experiences with the course and perspectives on the use of self-compassion in care.

    Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.

  8. Adjustment

    Measured using the Coping with MS Scale. Answers are assessed using a 5-point Likert scale and a mean per subscale group will be reported. Higher values indicate greater tendency to use coping strategies.

    Time frame: Measured at baseline, 8-week follow-up, and 3-month follow-up.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Apr 2025, 3 months later.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 3 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Mar 29, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Apr 30, 2025
CompletionEst.
Apr 30, 2025
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06337903
Lead sponsor
Robert Simpson
Responsible party
Robert Simpson (Investigator, Unity Health Toronto) — Sponsor-investigator
First posted
Mar 29, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Apr 30, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Dec 6, 2024

Study contacts

Robert Simpson, PhD
Contact
Robert.Simpson@unityhealth.to
416-360-4000 ext. 40047
Jillian Scandiffio, MSc
Contact
jillian.scandiffio@unityhealth.to
416-360-4000 ext. 40047
Robert Simpson, PhD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion